Genentech's stock hop

The price of Genentech stock went up yesterday afternoon, closing at $83.14 after climbing 1.9 percent. Perhaps we already are seeing a pharma comeback as the Pfizer-Wyeth merger progresses, and perhaps Genentech stock prices will continue to rise until Roche--or someone else--makes it an offer it cannot refuse.  Report.

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.